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ions can be developed to prevent these errors before they
ccur.
oi:10.1016/j.ijid.2010.02.2029
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omparison of the effectiveness of low dose Indi-
avir/ritonavir (IDV/r) versus Atazanavir/ritonavir (ATV/r)
ased antiretroviral therapy in NNRTI experienced HIV-1
nfected patients in India
. Patel1,∗, A.K. Patel1, J.K. Patel1, E. Naik2, J. Duan2, R.
anjan1, S. Hamisu2
Vedanta Institute of Medical Sciences, 380009, Gujarat,
ndia
University of South Florida, Tampa, FL, USA
Background: Currently, data on the effectiveness of sec-
nd line antiretroviral regimens using IDV/r and ATV/r along
ith two back bone nucleosides in resource poor settings
s limited. It is important to compare the potency and efﬁ-
acy of each regimen in order to establish utility on clinical
utcomes. We sought to evaluate viro-immunologic deter-
inants of response to IDV400/r BID and ATV300/r QD in
re-treated HIV-infected patients.
Methods: Prospective cohort study on 441 patients who
xperienced immunological or clinical failure to ﬁrst line
NRTI-based treatment and were enrolled in a 96-week
tudy follow-up. Based on the patients ability to pay, 321
72.8%) and 120 (27.2%) patients were prescribed reg-
mens containing low dose of IDV/r 400/100mg BID or
TV/r 300/100mg QD with 2NRTI, respectively. Successful
mmunologic response to treatment was deﬁned by annual
ise in absolute CD4 count of 100/cmm or more from base-
ine, while successful virologic response was deﬁned by
VL < 400 copies/ml at 12 or 24 weeks after initiation of
reatment. Multivariate Cox Proportional Hazards Model was
sed to assess comparative effectiveness of treatment regi-
ens with correction for intra-cluster correlation by means
f the Robust Sandwich Estimator.
Results: Both the groups had similar age, sex and weight
istribution. (p = 0.302, 0.232 & 0.459 respectively). A total
f 63 patients (14.8%) had failed second line treatments, 53
atients (17.2%) were using IDV/r while 10 patients (8.5%)
ere on ATV/r. Patients who took IDV/r were more than
wice as likely to experience treatment failure as com-
ared to those on ATV/r (HR 2.18; 95% CI 1.14, 4.15). A
igniﬁcant treatment-response interaction was observed for
atient weight and prior combination of NRTI use. Success-
ul response was not different between the two groups when
atients weighed < 55 kg at baseline (log rank p value = 1.00)
n contrast to the ﬁndings among individuals weighing ‘‘55 kg
p = <0.0001). Patients with one NRTI recycled, ATV/r was
ound to be superior to IDV/r (p = 0.01) while among those
ith both NRTI recycled, there was no difference in response
o either group (p = 0.61).
Conclusion: We found that Successful response to second
ine therapy was twice as likely in the ATV/r group; however,
his difference was eliminated in patients less than 55 kg.
oi:10.1016/j.ijid.2010.02.2030
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RTI resistance proﬁle of the subtype F HIV-1 strains from
hildren and adolescents treated with multiple antiretro-
iral drugs
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. Merisescu5
Institute of Infectious Diseases ‘‘Prof. dr. Matei Bals’’,
ucharest, sector 2, Romania
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ucharest, Romania
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ucharest, Romania
Institute of Infectious Disease ‘‘Prof. dr. Matei Bals’’,
ucharest, Romania
Institute of Infectious Diseases, Bucharest, Romania
Background: The HIV epidemic in Romania is character-
zed by the existence of a large cohort of children and
dolescents that have been infected in the late eighties.
ost of these patients have been under treatment for the
ast ten years: all of them are currently on HAART but
heir majority has experienced a period (years) of either
onotherapy (AZT) or bitherapy (AZT with 3TC or ddC). This
tudy examines resistance proﬁles in the RT gene of HIV-1
trains obtained from these patients.
Methods: We have studied resistance tests on antiretro-
iral therapy of experienced children’s and adolescents with
IV infection and AIDS hospitalized in National Institute
f Infectious Diseases ‘‘Prof. dr. Matei Bal#’’. On these
atients we have evaluated: antiretroviral therapy, number
f antiretroviral schemes, the type of resistance muta-
ions selected on Nucleoside Reverstranscriptase Inhibitors
NRTI’s) and the implications on to established of antiretro-
iral therapy, also.
Results: The most frequent mutations were: M184V/I -
8.8%, T215F/Y — 74.4%, D67N — 68.2%, K219E/Q — 66.6%,
70R — 56.9%, M41L — 41.4%. The thymidine analogue
utations (TAMs) were common and frequently associated
ith M184V. Within the TAM group, T215F/Y was frequently
ssociated with D67N, K70R and/or K219E/Q. V75T/V was
ssociated with K219E but only seldom with K219Q. The mul-
iresistention on experimented HIV infected children was
.2% (Q151M, 69ins, K65R).
Conclusion: The mutation associations in the RT gene
f the subtype F HIV-1 strains are partly different from
hose communicated for the subtype B strains and therefore
equire further scrutiny.
oi:10.1016/j.ijid.2010.02.2031
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mplementation of HLA-B*5701 genetic screening prior to
bacavir prescription in Georgia
. Dvali ∗, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M.
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Background: A hypersensitivity reaction to abacavir
evelops in approximately 2-8% of patients receiving this
